These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

353 related items for PubMed ID: 16427383

  • 1. Glanzmann's thrombasthenia treatment: a prospective observational registry on the use of recombinant human activated factor VII and other hemostatic agents.
    Poon MC, Zotz R, Di Minno G, Abrams ZS, Knudsen JB, Laurian Y.
    Semin Hematol; 2006 Jan; 43(1 Suppl 1):S33-6. PubMed ID: 16427383
    [Abstract] [Full Text] [Related]

  • 2. New Insights Into the Treatment of Glanzmann Thrombasthenia.
    Poon MC, Di Minno G, d'Oiron R, Zotz R.
    Transfus Med Rev; 2016 Apr; 30(2):92-9. PubMed ID: 26968829
    [Abstract] [Full Text] [Related]

  • 3. Clinical use of recombinant human activated factor VII (rFVIIa) in the prevention and treatment of bleeding episodes in patients with Glanzmann's thrombasthenia.
    Poon MC.
    Vasc Health Risk Manag; 2007 Apr; 3(5):655-64. PubMed ID: 18078017
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The use of recombinant factor VIla in a primigravida with Glanzmann's thrombasthenia during delivery.
    Kale A, Bayhan G, Yalinkaya A, Yayla M.
    J Perinat Med; 2004 Apr; 32(5):456-8. PubMed ID: 15493726
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Glanzmann's thrombasthenia (defective platelet integrin alphaIIb-beta3): proposals for management between evidence and open issues.
    Di Minno G, Coppola A, Di Minno MN, Poon MC.
    Thromb Haemost; 2009 Dec; 102(6):1157-64. PubMed ID: 19967146
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The international, prospective Glanzmann Thrombasthenia Registry: treatment modalities and outcomes of non-surgical bleeding episodes in patients with Glanzmann thrombasthenia.
    Di Minno G, Zotz RB, d'Oiron R, Bindslev N, Di Minno MN, Poon MC, Glanzmann Thrombasthenia Registry Investigators.
    Haematologica; 2015 Aug; 100(8):1031-7. PubMed ID: 26001793
    [Abstract] [Full Text] [Related]

  • 16. Glanzmann's thrombasthenia proposed optimal management during surgery and delivery.
    Bell JA, Savidge GF.
    Clin Appl Thromb Hemost; 2003 Apr; 9(2):167-70. PubMed ID: 12812388
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Platelet transfusion in a patient affected by Glanzmann's thrombasthenia with antibodies against GPIIb-IIIa.
    Conte R, Cirillo D, Ricci F, Tassi C, Tazzari PL.
    Haematologica; 1997 Apr; 82(1):73-4. PubMed ID: 9107089
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Successful surgery using recombinant factor VIIa for recurrent, idiopathic nonulcer duodenal bleeding in a patient with Glanzmann's thrombasthenia.
    van Buuren HR, Wielenga JJ.
    Dig Dis Sci; 2002 Sep; 47(9):2134-6. PubMed ID: 12353868
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.